PE20140005A1 - Tableta oralmente desintegradora - Google Patents
Tableta oralmente desintegradoraInfo
- Publication number
- PE20140005A1 PE20140005A1 PE2013001336A PE2013001336A PE20140005A1 PE 20140005 A1 PE20140005 A1 PE 20140005A1 PE 2013001336 A PE2013001336 A PE 2013001336A PE 2013001336 A PE2013001336 A PE 2013001336A PE 20140005 A1 PE20140005 A1 PE 20140005A1
- Authority
- PE
- Peru
- Prior art keywords
- orally disintegrating
- disintegrating tablet
- iii
- layer containing
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE UNA TABLETA ORALMENTE DESINTEGRADORA QUE COMPRENDE DOS CAPAS: A) UNA PRIMERA CAPA QUE CONTIENE i) GRANULOS FINOS ENTERICOS QUE COMPRENDEN UN INHIBIDOR DE BOMBA DE PROTONES TAL COMO LANSOPRAZOL, OMEPRAZOL, RABEPRAZOL O PANTOPRAZOL, ii) UN ANTIACIDO TAL COMO UNA MEZCLA DE CARBONATO DE MAGNESIO Y GLICINATO DE ALUMINIO EN UNA CANTIDAD DE 10 A 100MG, Y iii) UN DESINTEGRANTE TAL COMO CROSPOVIDONA Y ALUMINOMETASILICATO DE MAGNESIO; Y B) UNA SEGUNDA CAPA QUE CONTIENE i) ACIDO ACETILSALICILICO EN UNA CANTIDAD DE 70 A 120MG, ii) UN LUBRICANTE TAL COMO ACEITE HIDROGENADO, Y iii) CARBOXIMETILCELULOSA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ULCERA GASTRICA O DUODENAL EN SU ETAPA INICIAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010270276 | 2010-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140005A1 true PE20140005A1 (es) | 2014-01-23 |
Family
ID=46172031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001336A PE20140005A1 (es) | 2010-12-03 | 2011-12-02 | Tableta oralmente desintegradora |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130243859A1 (es) |
| EP (1) | EP2647381A4 (es) |
| JP (1) | JP6037840B2 (es) |
| KR (1) | KR101908748B1 (es) |
| CN (1) | CN103338774A (es) |
| AU (1) | AU2011337549A1 (es) |
| BR (1) | BR112013013571A2 (es) |
| CA (1) | CA2819460C (es) |
| CL (1) | CL2013001566A1 (es) |
| CO (1) | CO6721054A2 (es) |
| CR (1) | CR20130287A (es) |
| DO (1) | DOP2013000122A (es) |
| EA (1) | EA201390814A1 (es) |
| EC (1) | ECSP13012717A (es) |
| MX (1) | MX2013006247A (es) |
| MY (1) | MY180677A (es) |
| PE (1) | PE20140005A1 (es) |
| SG (1) | SG190717A1 (es) |
| TN (1) | TN2013000229A1 (es) |
| WO (1) | WO2012074110A1 (es) |
| ZA (1) | ZA201304366B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2561098T3 (es) | 2011-11-30 | 2016-02-24 | Takeda Pharmaceutical Company Limited | Comprimido recubierto en seco |
| WO2013183497A1 (ja) | 2012-06-05 | 2013-12-12 | 武田薬品工業株式会社 | 有核錠 |
| CA2913106A1 (en) * | 2013-05-21 | 2014-11-27 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablet |
| JP2015020964A (ja) * | 2013-07-17 | 2015-02-02 | 日本曹達株式会社 | ヒドロキシプロピルセルロース |
| KR20170083071A (ko) | 2014-11-11 | 2017-07-17 | 시오노기 앤드 컴파니, 리미티드 | 광에 대해서 불안정한 약물을 함유하는 다층 정제 |
| EP3236952B1 (en) * | 2014-12-23 | 2019-07-03 | KRKA, d.d., Novo mesto | Pharmaceutical tablet composition |
| WO2016148264A1 (ja) | 2015-03-19 | 2016-09-22 | 第一三共株式会社 | 着色剤を含有する固形製剤 |
| KR102426821B1 (ko) * | 2015-03-19 | 2022-07-28 | 다이이찌 산쿄 가부시키가이샤 | 항산화제를 함유하는 고형 제제 |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| JP7050484B2 (ja) * | 2017-12-26 | 2022-04-08 | ライオン株式会社 | 積層錠、医薬製剤及び積層錠の製造方法 |
| TWI845532B (zh) | 2018-07-30 | 2024-06-21 | 日商第一三共股份有限公司 | 含安定劑之醫藥品的固體製劑 |
| KR20220065997A (ko) * | 2020-11-13 | 2022-05-23 | (주)휴온스 | 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법 |
| CN113230221B (zh) * | 2021-04-06 | 2022-11-04 | 北京诚济制药股份有限公司 | 一种铝镁匹林片(ⅱ) |
| KR20230149188A (ko) | 2022-04-19 | 2023-10-26 | 한미약품 주식회사 | 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물 |
| CN119072315A (zh) | 2022-04-19 | 2024-12-03 | 韩美药品株式会社 | 包含乙酰水杨酸和质子泵抑制剂的药物组合物 |
| KR20240043707A (ko) | 2022-09-27 | 2024-04-03 | 한미약품 주식회사 | 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
| JP2820829B2 (ja) | 1991-03-07 | 1998-11-05 | 武田薬品工業株式会社 | 有核散剤およびその製造方法 |
| DK0723777T3 (da) * | 1993-10-12 | 2002-10-28 | Mitsubishi Pharma Corp | Tablet indeholdende enteriske granuler |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法 |
| TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| CA2407208C (en) | 2000-04-28 | 2010-08-17 | Takeda Chemical Industries, Ltd. | Process for producing optically active sulfoxide derivative |
| DE60131649T2 (de) | 2000-05-15 | 2008-10-30 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung eines kristalls |
| JP2002029964A (ja) * | 2000-07-11 | 2002-01-29 | Lion Corp | 固形医薬組成物 |
| JP2002154966A (ja) * | 2000-11-22 | 2002-05-28 | Taisho Pharmaceut Co Ltd | アセチルサリチル酸アルミニウム含有組成物 |
| TWI290922B (en) | 2000-12-01 | 2007-12-11 | Takeda Chemical Industries Ltd | Production method of crystals |
| EP2163241A1 (en) | 2001-06-01 | 2010-03-17 | Pozen, Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US8206741B2 (en) * | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| JP5138856B2 (ja) * | 2001-06-20 | 2013-02-06 | 武田薬品工業株式会社 | 錠剤の製造方法 |
| IL159584A0 (en) * | 2001-07-16 | 2004-06-01 | Astrazeneca Ab | Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| US6930099B2 (en) * | 2001-09-07 | 2005-08-16 | Advanced Medical Instruments | Composition for the treatment and prevention of endothelial dysfunction |
| US20050249806A1 (en) * | 2004-02-10 | 2005-11-10 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug |
| MXPA06013585A (es) * | 2004-05-25 | 2009-07-22 | Santarus Inc | Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para hacer y utilizar las mismas. |
| US20080166407A1 (en) * | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| AR057181A1 (es) * | 2005-11-30 | 2007-11-21 | Astra Ab | Nueva forma de dosificacion de combinacion |
| CN101316596A (zh) * | 2005-11-30 | 2008-12-03 | 阿斯利康(瑞典)有限公司 | 含有质子泵抑制剂和乙酰水杨酸作为活性成份的口服药物剂型 |
| US8202538B2 (en) * | 2006-06-26 | 2012-06-19 | Capricorn Pharma, Inc. | Orally disintegrating layered compositions |
| JP2009263305A (ja) * | 2008-04-28 | 2009-11-12 | Lion Corp | 多層錠剤およびその製造方法 |
| JPWO2009151116A1 (ja) * | 2008-06-13 | 2011-11-17 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
-
2011
- 2011-12-02 EP EP11844056.9A patent/EP2647381A4/en not_active Withdrawn
- 2011-12-02 MY MYPI2013002016A patent/MY180677A/en unknown
- 2011-12-02 CN CN2011800667861A patent/CN103338774A/zh active Pending
- 2011-12-02 BR BR112013013571A patent/BR112013013571A2/pt not_active IP Right Cessation
- 2011-12-02 AU AU2011337549A patent/AU2011337549A1/en not_active Abandoned
- 2011-12-02 EA EA201390814A patent/EA201390814A1/ru unknown
- 2011-12-02 KR KR1020137017448A patent/KR101908748B1/ko not_active Expired - Fee Related
- 2011-12-02 US US13/991,052 patent/US20130243859A1/en not_active Abandoned
- 2011-12-02 WO PCT/JP2011/077978 patent/WO2012074110A1/ja active Application Filing
- 2011-12-02 CA CA2819460A patent/CA2819460C/en not_active Expired - Fee Related
- 2011-12-02 SG SG2013041298A patent/SG190717A1/en unknown
- 2011-12-02 JP JP2012546960A patent/JP6037840B2/ja active Active
- 2011-12-02 MX MX2013006247A patent/MX2013006247A/es not_active Application Discontinuation
- 2011-12-02 PE PE2013001336A patent/PE20140005A1/es not_active Application Discontinuation
-
2013
- 2013-05-29 TN TNP2013000229A patent/TN2013000229A1/fr unknown
- 2013-05-31 CL CL2013001566A patent/CL2013001566A1/es unknown
- 2013-05-31 DO DO2013000122A patent/DOP2013000122A/es unknown
- 2013-06-13 ZA ZA2013/04366A patent/ZA201304366B/en unknown
- 2013-06-13 CR CR20130287A patent/CR20130287A/es not_active Application Discontinuation
- 2013-06-25 EC ECSP13012717 patent/ECSP13012717A/es unknown
- 2013-07-03 CO CO13156481A patent/CO6721054A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201304366B (en) | 2014-02-26 |
| MY180677A (en) | 2020-12-05 |
| CR20130287A (es) | 2013-10-07 |
| US20130243859A1 (en) | 2013-09-19 |
| CN103338774A (zh) | 2013-10-02 |
| KR101908748B1 (ko) | 2018-10-16 |
| DOP2013000122A (es) | 2013-12-15 |
| JPWO2012074110A1 (ja) | 2014-05-19 |
| CO6721054A2 (es) | 2013-07-31 |
| AU2011337549A1 (en) | 2013-07-04 |
| EA201390814A1 (ru) | 2013-11-29 |
| BR112013013571A2 (pt) | 2016-10-11 |
| EP2647381A4 (en) | 2015-12-23 |
| MX2013006247A (es) | 2014-01-31 |
| EP2647381A1 (en) | 2013-10-09 |
| TN2013000229A1 (en) | 2014-11-10 |
| SG190717A1 (en) | 2013-07-31 |
| CL2013001566A1 (es) | 2014-05-02 |
| CA2819460C (en) | 2017-08-01 |
| ECSP13012717A (es) | 2013-12-31 |
| CA2819460A1 (en) | 2012-06-07 |
| WO2012074110A1 (ja) | 2012-06-07 |
| JP6037840B2 (ja) | 2016-12-07 |
| KR20130124344A (ko) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140005A1 (es) | Tableta oralmente desintegradora | |
| PE20140163A1 (es) | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| UA107967C2 (en) | Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan | |
| EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| AR089818A1 (es) | Inhibidor de la quinasa que regula la señal de la apoptosis | |
| MY167126A (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
| NO20081636L (no) | FAP - inhibitorer | |
| CL2012002356A1 (es) | Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras. | |
| CY1116852T1 (el) | Δισκια διπλης στιβαδας τα οποια περιεχουν ελβιτεγραβιρη, κοβισιστατη, εμτρισιταβινη και τενοφοβιρη | |
| NO20083836L (no) | N-hydroksyakrylamidforbindelser | |
| PE20110943A1 (es) | Formulacion oral solida de alisquireno | |
| WO2008124129A3 (en) | Treating hiv with a m-csf effector kinase inhibitor like imatinib | |
| UA107784C2 (en) | Inhibitor of melanin production | |
| PE20142182A1 (es) | Inhibidores de iap | |
| SV2010003723A (es) | Derivados de piperidina 3,4-sustituida como inhibidores de renina | |
| AR082660A1 (es) | Composiciones farmaceuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
| AR072493A1 (es) | Desentintado de un sustrato celulosico usando hidroxido de magnesio | |
| PE20141035A1 (es) | Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y raf | |
| ATE473211T1 (de) | Renininhibitoren | |
| PE20150402A1 (es) | Formulacion de una capsula farmaceutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa | |
| DOP2015000296A (es) | Formulacion oral para el tratamiento de enfermedades cardiovasculares | |
| PE20091030A1 (es) | Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa | |
| MX386908B (es) | Formulacion de liberacion modificada de naproxeno sodico. | |
| PE20150935A1 (es) | Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio | |
| TR201007867T2 (tr) | Uzatılmış salım sağlayan gliklazid tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |